OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HOJI.PK55

House of Jane Inc.

Healthcare Facilities & ServicesVerified

House of Jane Inc. has a basic and diluted share count of 11,031,895 shares outstanding, indicating no dilution from potential share issuance at this time. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. This lack of financial data limits the ability to evaluate the company's short-term financial health and operational stability. Profitability and return metrics are not available for House of Jane Inc., which makes it difficult to compare its performance against industry benchmarks or preferred metrics. Without these figures, it is impossible to determine whether the company is generating returns that are in line with or above the industry median. The company's segments and geographic exposure are not disclosed in the available data, making it impossible to assess revenue concentration or geographic diversification. This lack of information hinders the ability to evaluate the company's exposure to regional economic conditions or market-specific risks. Growth trajectory data is not available for House of Jane Inc., and there are no numeric deltas provided for the current or next fiscal year. Without historical revenue data or forward-looking guidance, it is not possible to assess the company's growth potential or trajectory. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in the source documents. Additionally, the company's dilution potential is currently low, but the lack of financial transparency increases the uncertainty around future capital structure decisions. Recent events, including filings and transcripts, are not disclosed in the available data, which limits the ability to evaluate the company's recent performance or strategic direction.

30-day price · HOJI.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyHouse of Jane Inc.
TickerHOJI.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. House of Jane Inc. operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry with a confidence level of 0.92.

House of Jane Inc. has a basic and diluted share count of 11,031,895 shares outstanding, indicating no dilution from potential share issuance at this time. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. This lack of financial data limits the ability to evaluate the company's short-term financial health and operational stability. Profitability and return metrics are not available for House of Jane Inc., which makes it difficult to compare its performance against industry benchmarks or preferred metrics. Without these figures, it is impossible to determine whether the company is generating returns that are in line with or above the industry median. The company's segments and geographic exposure are not disclosed in the available data, making it impossible to assess revenue concentration or geographic diversification. This lack of information hinders the ability to evaluate the company's exposure to regional economic conditions or market-specific risks. Growth trajectory data is not available for House of Jane Inc., and there are no numeric deltas provided for the current or next fiscal year. Without historical revenue data or forward-looking guidance, it is not possible to assess the company's growth potential or trajectory. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in the source documents. Additionally, the company's dilution potential is currently low, but the lack of financial transparency increases the uncertainty around future capital structure decisions. Recent events, including filings and transcripts, are not disclosed in the available data, which limits the ability to evaluate the company's recent performance or strategic direction.
Key takeaways
  • House of Jane Inc. has no dilution from potential share issuance at this time.
  • The company's liquidity risk could not be assessed due to missing balance-sheet data.
  • Profitability and return metrics are not available, limiting performance comparisons.
  • Growth trajectory and historical revenue data are not disclosed.
  • Recent events and strategic direction are not available in the source documents.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4
FY-3
FY-2
FY-1
FY0
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3
FY-2
FY-1
FY0
PeriodOCFCapExFCFSBC
FY-4
FY-3
FY-2
FY-1
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricHOJI.PKActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 01:17 UTC#d37cfd91
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 03:31 UTCJob: 1757d764